Eli Lilly’s Retatrutide Achieves 12.8–14.4% Weight Loss in ATTAIN-1
LLY•Retatrutide (Foundayo) delivered weight loss of 12.8–14.4% (28–30 lbs) in ATTAIN-1 and 18.5–27.8 lbs in ATTAIN-2, with over 50% achieving at least 15% reduction and outperforming Zepbound by ~3 percentage points placebo-adjusted. Shares rose following presentations at the ADA conference, and Citi reaffirmed conviction in Lilly’s incretin pipeline.
1. Retatrutide Clinical Trial Results
In ATTAIN-1 trials, Foundayo delivered weight loss of 12.8–14.4% (28–30 lbs), while ATTAIN-2 participants lost 18.5–27.8 lbs; over half achieved at least 15% reduction. Placebo-adjusted data indicated retatrutide outperformed Zepbound by roughly three percentage points, highlighting its potential efficacy advantage.
2. Market Reaction and Analyst Commentary
Shares rose in early trading following presentations at the ADA conference as investors digested the robust efficacy data. Citi analysts maintained firm conviction in Lilly’s incretin pipeline, emphasizing the company’s strategy of a diversified portfolio rather than relying on single-blockbuster therapies.
3. Competitive Landscape
Novo Nordisk’s recent Phase 3 and Phase 2 obesity and diabetes drug updates, including CagriSema’s impressive HbA1c and weight-loss results and Wegovy’s rapid prescription uptake, underscore intensifying competition. Lilly’s retatrutide, combining amylin analog and GLP-1 agonist mechanisms, aims to differentiate by delivering substantial placebo-adjusted weight reduction.
